ACTRN12605000115639
Recruiting
Phase 2
A randomised phase II study to evaluate the effectiveness of botulinum toxin to delay, and possibly prevent, progressive foot deformities in children with Charcot-Marie-Tooth (CMT) disease.
The Children's Hospital at Westmead0 sites10 target enrollmentAugust 9, 2005
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Charcot-Marie-Tooth disease
- Sponsor
- The Children's Hospital at Westmead
- Enrollment
- 10
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Children will have a non\-fixed bilateral pes cavus due to Charcot Marie Tooth disease type 1A. All patients will have a definite clinical diagnosis of Charcot\-Marie\-Tooth disease, which will be confirmed where possible by neurophysiologic testing and/or genetic testing of the patient or an affected first\-degree relative. The diagnosis of pes cavus will be based upon clinical examination and foot X\-rays.
Exclusion Criteria
- •No exclusion criteria
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Effects of natural seaweed extract (GFS) on mobilisation of human bone marrow stem cells and immune system activatioormal volunteersNormal volunteersOther - Research that is not of generic health relevance and not applicable to specific health categories listed aboveInflammatory and Immune System - Normal development and function of the immune systemACTRN12605000021673Tas100
Not yet recruiting
Phase 2
A randomised phase 2 study of carboplatin with oral vinorelbine followed by maintenance therapy with oral vinorelbine or erlotinib in elderly patients with metastatic non-small cell lung cancer.on Small Cell Lung CancerNon Small Cell Lung CancerCancer - Lung - Non small cellACTRN12612000473864Southern Health100
Active, not recruiting
Not Applicable
A phase II randomised study to investigate the effects of Bevacizumab on cell proliferation and on pCR in patients with locally advanced operable breast cancer - NDEUCTR2005-005048-19-ITISTITUTO EUROPEO DI ONCOLOGIA120
Active, not recruiting
Not Applicable
EFFECT: A randomized phase II study to evaluate the EFficacy and impact on Function of two different doses of nab-paclitaxEl in elderly patients with advanCed breasT cancerPatients aged 65 years or older with histologically or cytologically confirmed breast cancer, locally recurrent and/or metastaticany estrogen/progesterone receptor statusHER2 receptor negative OR HER2 positive but with contraindication to anti-HER2 therapyMedDRA version: 14.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-002707-18-ITFONDAZIONE SANDRO PITIGLIANI PER LA LOTTA CONTRO I TUMORI-ONLUS
Completed
Phase 2
A randomized phase II study to assess the efficacy of acid blocker on prevention of hemorrhage and healing of ulcers after endoscopic submucosal dissection(ESD) for gastric neoplasmsJPRN-UMIN000017320Osaka Medical Center for Cancer and Cardiovascular Diseases140